Ali Badiee

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7944802/publications.pdf

Version: 2024-02-01

96 papers	2,565 citations	159585 30 h-index	223800 46 g-index
99 all docs	99 docs citations	99 times ranked	3065 citing authors

#	Article	IF	Citations
1	AE36 HER2/neu-derived peptide linked to positively charged liposomes with CpG-ODN as an effective therapeutic and prophylactic vaccine for breast cancer. Journal of Drug Delivery Science and Technology, 2022, 67, 102904.	3.0	6
2	Nanocarriers Call the Last Shot in the Treatment of Brain Cancers. Technology in Cancer Research and Treatment, 2022, 21, 153303382210809.	1.9	11
3	Recent advancements in nanoparticle-mediated approaches for restoration of multiple sclerosis. Journal of Controlled Release, 2022, 343, 620-644.	9.9	9
4	Redox-sensitive doxorubicin liposome: a formulation approach for targeted tumor therapy. Scientific Reports, 2022, 12, .	3.3	13
5	miR-155 influences cell-mediated immunity in Balb/c mice treated with aflatoxin M₁. Drug and Chemical Toxicology, 2021, 44, 39-46.	2.3	7
6	A validated 1H-NMR method for quantitative analysis of DOTAP lipid in nanoliposomes containing soluble Leishmania antigen. Journal of Pharmaceutical and Biomedical Analysis, 2021, 194, 113809.	2.8	5
7	Preparation of liposomes containing IFN-gamma and their potentials in cancer immunotherapy: In vitro and in vivo studies in a colon cancer mouse model. Life Sciences, 2021, 264, 118605.	4.3	19
8	Improving anti-tumour efficacy of PEGylated liposomal doxorubicin by dual targeting of tumour cells and tumour endothelial cells using anti-p32 CGKRK peptide. Journal of Drug Targeting, 2021, 29, 617-630.	4.4	25
9	Efficacy Comparison of TAT Peptide-Functionalized PEGylated Liposomal Doxorubicin in C26 and B16F0 Tumor Mice Models. International Journal of Peptide Research and Therapeutics, 2021, 27, 2099-2109.	1.9	3
10	Ex vivo dendritic cell-based (DC) vaccine pulsed with a low dose of liposomal antigen and CpG-ODN improved PD-1 blockade immunotherapy. Scientific Reports, 2021, 11, 14661.	3.3	19
11	Multi-antigen vaccination with LPD nanoparticles containing rgp63 and rLmaC1N proteins induced effective immune response against leishmaniasis in animal model. Journal of Drug Delivery Science and Technology, 2021, 64, 102633.	3.0	0
12	pH-Sensitive PEGylated Liposomal Silybin: Synthesis, In Vitro and In Vivo Anti-Tumor Evaluation. Journal of Pharmaceutical Sciences, 2021, 110, 3919-3928.	3.3	11
13	Comparison of two routes of administration of a cationic liposome formulation for a prophylactic DC vaccination in a murine melanoma model. International Immunopharmacology, 2021, 98, 107833.	3.8	4
14	The impact of nanocarriers in the induction of antigen-specific immunotolerance in autoimmune diseases. Journal of Controlled Release, 2021, 339, 274-283.	9.9	8
15	Development of a novel formulation method to prepare liposomal Epacadostat. European Journal of Pharmaceutical Sciences, 2021, 165, 105954.	4.0	4
16	Development of a stable and high loaded liposomal formulation of lapatinib with enhanced therapeutic effects for breast cancer in combination with CaelyxÂ®: In vitro and in vivo evaluations. Colloids and Surfaces B: Biointerfaces, 2021, 207, 112012.	5.0	4
17	An insight into the role of liposomal therapeutics in the reversion of multiple sclerosis. Expert Opinion on Drug Delivery, 2021, 18, 1795-1813.	5.0	4
18	Sphingomyelin liposome bearing whole lysate antigens induce strong Th2 immune response in BALB/c mice. Iranian Journal of Basic Medical Sciences, 2021, 24, 222-231.	1.0	0

#	Article	IF	Citations
19	Development of nano-carriers forLeishmaniavaccine delivery. Expert Opinion on Drug Delivery, 2020, 17, 167-187.	5.0	14
20	Development of an effective liposomal cholesterol ester transfer protein (CETP) vaccine for protecting against atherosclerosis in rabbit model. Pharmaceutical Development and Technology, 2020, 25, 432-439.	2.4	3
21	Redox-sensitive nanoscale drug delivery systems for cancer treatment. International Journal of Pharmaceutics, 2020, 589, 119882.	5.2	65
22	Preparation, characterization and improved release profile of ibuprofen-phospholipid association. Journal of Drug Delivery Science and Technology, 2020, 60, 101951.	3.0	18
23	Preparation and characterization of stable nanoliposomal formulations of curcumin with high loading efficacy: In vitro and in vivo anti-tumor study. International Journal of Pharmaceutics, 2020, 580, 119211.	5.2	46
24	Ex vivo-generated dendritic cell-based vaccines in melanoma: the role of nanoparticulate delivery systems. Immunotherapy, 2020, 12, 333-349.	2.0	12
25	Vaccination with dendritic cells pulsed ex vivo with gp100 peptide-decorated liposomes enhances the efficacy of anti PD-1 therapy in a mouse model of melanoma. Vaccine, 2020, 38, 5665-5677.	3.8	15
26	A Phospholipase-A Activity in Soluble Leishmania Antigens Causes Instability of Liposomes. Current Drug Delivery, 2020, 17, 806-814.	1.6	2
27	Liposomal gp100 vaccine combined with CpG ODN sensitizes established B16F10 melanoma tumors to anti PD-1 therapy. Iranian Journal of Basic Medical Sciences, 2020, 23, 1065-1077.	1.0	7
28	Preparation of nanoliposomes containing HER2/neu (P5+435) peptide and evaluation of their immune responses and anti-tumoral effects as a prophylactic vaccine against breast cancer. PLoS ONE, 2020, 15, e0243550.	2.5	11
29	A novel formulation of Mtb72F DNA vaccine for immunization against tuberculosis. Iranian Journal of Basic Medical Sciences, 2020, 23, 826-832.	1.0	0
30	Preparation, characterization and in vivo evaluation of alginate-coated chitosan and trimethylchitosan nanoparticles loaded with PR8 influenza virus for nasal immunization. Asian Journal of Pharmaceutical Sciences, 2019, 14, 216-221.	9.1	46
31	Development and characterization of a multiparticulate drug delivery system containing indomethacin-phospholipid complex to improve dissolution rate. Journal of Drug Delivery Science and Technology, 2019, 53, 101177.	3.0	6
32	Cell cytotoxicity, immunostimulatory and antitumor effects of lipid content of liposomal delivery platforms in cancer immunotherapies. A comprehensive in-vivo and in-vitro study. International Journal of Pharmaceutics, 2019, 567, 118492.	5.2	21
33	Enhancement of the effect of BCG vaccine against tuberculosis using DDA/TDB liposomes containing a fusion protein of HspX, PPE44, and EsxV. Artificial Cells, Nanomedicine and Biotechnology, 2019, 47, 370-377.	2.8	18
34	Development of topical liposomes containing miltefosine for the treatment of Leishmania major infection in susceptible BALB/c mice. Acta Tropica, 2019, 196, 142-149.	2.0	35
35	MPL nano-liposomal vaccine containing P5 HER2/neu-derived peptide pulsed PADRE as an effective vaccine in a mice TUBO model of breast cancer. Journal of Controlled Release, 2019, 303, 223-236.	9.9	58
36	P435 HER2/neu-derived peptide conjugated to liposomes containing DOPE as an effective prophylactic vaccine formulation for breast cancer. Artificial Cells, Nanomedicine and Biotechnology, 2019, 47, 664-672.	2.8	29

#	Article	IF	Citations
37	Long-term generation of antiPCSK9 antibody using a nanoliposome-based vaccine delivery system. Atherosclerosis, 2019, 283, 69-78.	0.8	49
38	Liposomal nanocarriers for statins: A pharmacokinetic and pharmacodynamics appraisal. Journal of Cellular Physiology, 2019, 234, 1219-1229.	4.1	18
39	Preparation of nanoliposomes linked to HER2/neuâ€derived (P5) peptide containing MPL adjuvant as vaccine against breast cancer. Journal of Cellular Biochemistry, 2019, 120, 1294-1303.	2.6	13
40	Increasing Cellular Immune Response in Liposomal Formulations of DOTAP Encapsulated by Fusion Protein Hspx, PPE44, And Esxv, as a Potential Tuberculosis Vaccine Candidate. Reports of Biochemistry and Molecular Biology, 2019, 7, 156-166.	1.4	5
41	Evaluation of Immune Response against Leishmaniasis in BALB/c Mice Immunized with Cationic DOTAP/DOPE/CHOL Liposomes Containing Soluble Antigens. Iranian Journal of Parasitology, 2019, 14, 68-77.	0.6	2
42	Liposomal CpG-ODN: An in vitro and in vivo study on macrophage subtypes responses, biodistribution and subsequent therapeutic efficacy in mice models of cancers. European Journal of Pharmaceutical Sciences, 2018, 119, 159-170.	4.0	40
43	Cationic liposomes formulated with a novel whole Leishmania lysate (WLL) as a vaccine for leishmaniasis in murine model. Immunobiology, 2018, 223, 493-500.	1.9	17
44	Immunization against PR8 influenza virus with chitosan-coated ISCOMATRIX nanoparticles. Artificial Cells, Nanomedicine and Biotechnology, 2018, 46, 587-593.	2.8	3
45	Immunogenicity and antitumor activity of the superlytic Î»F7 phage nanoparticles displaying a HER2/neu-derived peptide AE37 in a tumor model of BALB/c mice. Cancer Letters, 2018, 424, 109-116.	7.2	25
46	A nano-liposome vaccine carrying E75, a HER-2/neu-derived peptide, exhibits significant antitumour activity in mice. Journal of Drug Targeting, 2018, 26, 365-372.	4.4	40
47	The role of LPD-nanoparticles containing recombinant major surface glycoprotein ofLeishmania(rgp63) in protection against leishmaniasis in murine model. Immunopharmacology and Immunotoxicology, 2018, 40, 72-82.	2.4	10
48	Lambda phage nanoparticles displaying HER2-derived E75 peptide induce effective E75-CD8+ T response. Immunologic Research, 2018, 66, 200-206.	2.9	30
49	The role of nanoliposome bilayer composition containing soluble antigen on maturation and activation of dendritic cells. Iranian Journal of Basic Medical Sciences, 2018, 21, 536-545.	1.0	3
50	Therapeutic Efficacy of Cisplatin Thermosensitive Liposomes upon Mild Hyperthermia in C26 Tumor Bearing BALB/c Mice. Molecular Pharmaceutics, 2017, 14, 712-721.	4.6	33
51	PNC27 anticancer peptide as targeting ligand significantly improved antitumor efficacy of Doxil in HDM2-expressing cells. Nanomedicine, 2017, 12, 1475-1490.	3.3	24
52	<scp>PEG</scp>ylation of cationic liposomes encapsulating soluble Leishmania antigens reduces the adjuvant efficacy of liposomes in murine model. Parasite Immunology, 2017, 39, e12492.	1.5	6
53	Nanoliposomes carrying HER2/neu-derived peptide AE36 with CpG-ODN exhibit therapeutic and prophylactic activities in a mice TUBO model of breast cancer. Immunology Letters, 2017, 190, 108-117.	2.5	29
54	Liposomal adjuvant development for leishmaniasis vaccines. Therapeutic Advances in Vaccines, 2017, 5, 85-101.	2.7	21

#	Article	IF	Citations
55	Stimulation of Tumor-Specific Immunity by p5 HER-2/neu Generated Peptide Encapsulated in Nano-liposomes with High Phase Transition Temperature Phospholipids. Current Drug Delivery, 2017, 14, 492-502.	1.6	11
56	Anti-atherosclerosis effect of different doses of CETP vaccine in rabbit model of atherosclerosis. Biomedicine and Pharmacotherapy, 2016, 81, 468-473.	5.6	5
57	Targeting, bio distributive and tumor growth inhibiting characterization of anti-HER2 affibody coupling to liposomal doxorubicin using BALB/c mice bearing TUBO tumors. International Journal of Pharmaceutics, 2016, 505, 89-95.	5.2	31
58	Coadminstration of L. major amastigote class I nuclease (rLmaCIN) with LPD nanoparticles delays the progression of skin lesion and the L. major dissemination to the spleen in BALB/c mice-based experimental setting. Acta Tropica, 2016, 159, 211-218.	2.0	15
59	Poly (I:C)-DOTAP cationic nanoliposome containing multi-epitope HER2-derived peptide promotes vaccine-elicited anti-tumor immunity in a murine model. Immunology Letters, 2016, 176, 57-64.	2.5	31
60	Tat peptide and hexadecylphosphocholine introduction into pegylated liposomal doxorubicin: An in vitro and in vivo study on drug cellular delivery, release, biodistribution and antitumor activity. International Journal of Pharmaceutics, 2016, 511, 236-244.	5.2	26
61	Improvement in the drug delivery and anti-tumor efficacy of PEGylated liposomal doxorubicin by targeting RNA aptamers in mice bearing breast tumor model. Colloids and Surfaces B: Biointerfaces, 2016, 139, 228-236.	5.0	62
62	Improved therapeutic activity of HER2 Affibody-targeted cisplatin liposomes in HER2-expressing breast tumor models. Expert Opinion on Drug Delivery, 2016, 13, 325-336.	5.0	41
63	The role of ISCOMATRIX bilayer composition to induce a cell mediated immunity and protection against leishmaniasis in BALB/c mice. Iranian Journal of Basic Medical Sciences, 2016, 19, 178-86.	1.0	6
64	A novel atheroprotective role of MF59-like adjuvant when co-administered with CETP vaccine in rabbit model of atherosclerosis. Iranian Journal of Basic Medical Sciences, 2016, 19, 1345-1352.	1.0	0
65	Apolipoprotein B-100-targeted negatively charged nanoliposomes for the treatment of dyslipidemia. Colloids and Surfaces B: Biointerfaces, 2015, 129, 71-78.	5.0	8
66	Targeting CD44 expressing cancer cells with anti-CD44 monoclonal antibody improves cellular uptake and antitumor efficacy of liposomal doxorubicin. Journal of Controlled Release, 2015, 220, 275-286.	9.9	152
67	Investigation of Hexadecylphosphocholine (miltefosine) usage in Pegylated liposomal doxorubicin as a synergistic ingredient: In vitro and in vivo evaluation in mice bearing C26 colon carcinoma and B16F0 melanoma. European Journal of Pharmaceutical Sciences, 2015, 80, 66-73.	4.0	23
68	Nanoliposome-mediated targeting of antibodies to tumors: IVIG antibodies as a model. International Journal of Pharmaceutics, 2015, 495, 162-170.	5.2	43
69	Development of a novel cyclic RGD peptide for multiple targeting approaches of liposomes to tumor region. Journal of Controlled Release, 2015, 220, 308-315.	9.9	69
70	Nanolipoparticles-mediated MDR1 siRNA delivery reduces doxorubicin resistance in breast cancer cells and silences MDR1 expression in xenograft model of human breast cancer. Iranian Journal of Basic Medical Sciences, 2015, 18, 385-92.	1.0	19
71	Preparation and characterization of different liposomal formulations containing P5 HER2/neu-derived peptide and evaluation of their immunological responses and antitumor effects. Iranian Journal of Basic Medical Sciences, 2015, 18, 506-13.	1.0	6
72	Development of RNA aptamers as molecular probes for HER2(+) breast cancer study using cell-SELEX. Iranian Journal of Basic Medical Sciences, 2015, 18, 576-86.	1.0	15

#	Article	IF	Citations
73	Immunoliposomes containing Soluble Leishmania Antigens (SLA) as a novel antigen delivery system in murine model of leishmaniasis. Experimental Parasitology, 2014, 146, 78-86.	1.2	27
74	P5 HER2/neu-derived peptide conjugated to liposomes containing MPL adjuvant as an effective prophylactic vaccine formulation for breast cancer. Cancer Letters, 2014, 355, 54-60.	7.2	58
75	The influence of phospholipid on the physicochemical properties and anti-tumor efficacy of liposomes encapsulating cisplatin in mice bearing C26 colon carcinoma. International Journal of Pharmaceutics, 2014, 473, 326-333.	5.2	34
76	A simple and effective approach for the treatment of dyslipidemia using anionic nanoliposomes. Colloids and Surfaces B: Biointerfaces, 2014, 122, 645-652.	5.0	9
77	Effective induction of anti-tumor immunity using p5 HER-2/neu derived peptide encapsulated in fusogenic DOTAP cationic liposomes co-administrated with CpG-ODN. Immunology Letters, 2014, 162, 87-93.	2.5	58
78	Optimization of a Method to Prepare Liposomes Containing HER2/Neu- Derived Peptide as a Vaccine Delivery System for Breast Cancer. Iranian Journal of Pharmaceutical Research, 2014, 13, 15-25.	0.5	23
79	Induction of protection against leishmaniasis in susceptible BALB/c mice using simple DOTAP cationic nanoliposomes containing soluble Leishmania antigen (SLA). Acta Tropica, 2013, 128, 528-535.	2.0	45
80	Improvement of pharmacokinetic and antitumor activity of PEGylated liposomal doxorubicin by targeting with N-methylated cyclic RGD peptide in mice bearing C-26 colon carcinomas. International Journal of Pharmaceutics, 2013, 458, 324-333.	5.2	90
81	Micro/nanoparticle adjuvants for antileishmanial vaccines: Present and future trends. Vaccine, 2013, 31, 735-749.	3.8	70
82	Sphingomyelin Liposomes Containing Soluble Leishmania major antigens Induced Strong Th2 Immune Response in BALB/c Mice. Iranian Journal of Basic Medical Sciences, 2013, 16, 965-72.	1.0	9
83	The role of liposomeâ€“protamineâ€“DNA nanoparticles containing CpG oligodeoxynucleotides in the course of infection induced by Leishmania major in BALB/c mice. Experimental Parasitology, 2012, 132, 313-319.	1.2	18
84	The role of liposome size on the type of immune response induced in BALB/c mice against leishmaniasis: rgp63 as a model antigen. Experimental Parasitology, 2012, 132, 403-409.	1.2	74
85	Liposomal SLA co-incorporated with PO CpG ODNs or PS CpG ODNs induce the same protection against the murine model of leishmaniasis. Vaccine, 2012, 30, 3957-3964.	3.8	45
86	Cationic liposomes containing soluble Leishmania antigens (SLA) plus CpG ODNs induce protection against murine model of leishmaniasis. Parasitology Research, 2012, 111, 105-114.	1.6	32
87	Comparison of in vivo Adjuvanticity of Liposomal PO CpG ODN with Liposomal PS CpG ODN: Soluble Leishmania Antigens as a Model. Iranian Journal of Basic Medical Sciences, 2012, 15, 1032-45.	1.0	8
88	The Role of Liposomal CpG ODN on the Course of L. major Infection in BALB/C Mice. Iranian Journal of Parasitology, 2010, 5, 47-54.	0.6	8
89	The role of liposome charge on immune response generated in BALB/c mice immunized with recombinant major surface glycoprotein of Leishmania (rgp63). Experimental Parasitology, 2009, 121, 362-369.	1.2	50
90	Enhancement of immune response and protection in BALB/c mice immunized with liposomal recombinant major surface glycoprotein of Leishmania (rgp63): The role of bilayer composition. Colloids and Surfaces B: Biointerfaces, 2009, 74, 37-44.	5.0	29

#	Article	IF	Citations
91	Coencapsulation of CpG Oligodeoxynucleotides with RecombinantLeishmania majorStress-Inducible Protein 1 in Liposome Enhances Immune Response and Protection against Leishmaniasis in Immunized BALB/c Mice. Vaccine Journal, 2008, 15, 668-674.	3.1	44
92	Enhanced delivery of immunoliposomes to human dendritic cells by targeting the multilectin receptor DEC-205. Vaccine, 2007, 25, 4757-4766.	3.8	43
93	The role of CpG ODN in enhancement of immune response and protection in BALB/c mice immunized with recombinant major surface glycoprotein of Leishmania (rgp63) encapsulated in cationic liposome. Vaccine, 2007, 25, 6107-6117.	3.8	82
94	Leishmania major: Immune response in BALB/c mice immunized with stress-inducible protein 1 encapsulated in liposomes. Experimental Parasitology, 2007, 115, 127-134.	1.2	59
95	Crystal Habit Modifications of Ibuprofen and Their Physicomechanical Characteristics. Drug Development and Industrial Pharmacy, 2001, 27, 803-809.	2.0	105
96	Evaluation of Immune Response against Leishmaniasis in BALB/c Mice Immunized with Cationic DOTAP/DOPE/CHOL Liposomes Containing Soluble Leishmania major Antigens. Iranian Journal of Parasitology, 0, , .	0.6	1